EPO Greenlights Claims Covering Preventative use of therapy targeting 5-HT4 Pathway and Expands Silo Pharma IP Portfolio

Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, announced that the European Patent Office (EPO) has issued a Rule 71(3) communication indicating its intent to grant a patent for an European patent application titled “Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress” (European Patent Application No. 20786878.7) that the Company has an exclusive license from Columbia University.

The allowed claims cover methods of preventing stress-induced fear and depressive-like behavior and associated affective disorders using selected serotonin 4 (5-HT4) receptor agonists — a differentiated approach targeting pathways associated with stress resilience rather than just symptom management.

“This is a high-value milestone that strengthens our global intellectual property position and underscores the potential of our 5-HT4 program,” said Eric Weisblum, CEO of Silo Pharma. “We believe this approach represents a compelling shift toward proactive treatment of stress-related disorders, which remain a massive and underserved market.”

The patent, once granted, is expected to protect major European markets, further enhancing Silo’s strategic positioning as it advances its pipeline. The Company is evaluating Unitary Patent protection and key national validations to maximize geographic coverage and long-term value.

With growing global focus on mental health and stress-related conditions, Silo Pharma continues to build a portfolio targeting next-generation CNS therapeutics with differentiated mechanisms of action.

About Silo Pharma, Inc.

Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease. Silo’s research is conducted in collaboration with leading universities and laboratories.